Faculty Profiles - FUJIWARA Toshiyoshi

MISC - FUJIWARA Toshiyoshi

Division display 141 - 160 of about 922 ／ All the affair displays >>

大腸癌におけるAZIN1RNA編集の意義

重安邦俊, 重安邦俊, GOEL A., 藤原俊義

肝臓 59 ( Supplement 2 ) 2018

Bevacizumab+mFOLFOX6療法が有効であった肝内胆管癌の一例

母里淑子, 永坂岳司, 楳田祐三, 重安邦俊, 吉田一博, 岸本浩行, 香川俊輔, 藤原俊義

日本臨床腫瘍学会学術集会(CD-ROM) 16th 2018

大腸癌における新規oncogenic small nucleolar RNA(oncSNOR)の探求

吉田一博, 重安邦俊, 楳田祐三, 吉田龍一, 信岡大輔, 杭瀬崇, 安井和也, 香川俊輔, 白川靖博, 八木孝仁, GOEL Ajay, 藤原俊義

日本消化器癌発生学会総会プログラム・抄録集 29th 2018

消化管外瘻を伴う炎症性腸疾患に対する腹腔鏡下手術の安全性

戸嶋俊明, 近藤善太, 小松泰浩, 三村直毅, 重安邦俊, 矢野修也, 母里淑子, 寺石文則, 岸本浩行, 香川俊輔, 藤原俊義

日本大腸肛門病学会雑誌(Web) 71 ( 9 ) 2018

StageIV大腸癌の原発巣切除後に長期予後が期待できる症例とは

寺石文則, 戸嶋俊明, 重安邦俊, 矢野修也, 母里淑子, 近藤喜太, 岸本浩行, 尾崎和秀, 藤原俊義

日本大腸肛門病学会雑誌(Web) 71 ( 9 ) 2018

回腸人工肛門狭窄のリスク因子の抽出と予防

重安邦俊, 母里淑子, 戸嶋俊明, 矢野修也, 近藤喜太, 岸本浩行, 寺石文則, 藤原俊義

日本大腸肛門病学会雑誌(Web) 71 ( 9 ) 2018

鉄キレート剤の幹細胞性制御による新規癌治療法の確立

大原利章, 大原利章, 桂佑貴, 野間和広, 鳴坂徹, 二宮卓之, 友野靖子, 田澤大, 香川俊輔, 白川靖博, 松川昭博, 藤原俊義

日本消化器癌発生学会総会プログラム・抄録集 29th 2018

食道癌におけるがん細胞及びがん関連線維芽細胞に対するDual-targeting Photoimmunotherapy

佐藤浩明, 野間和宏, 鳴坂徹, 河本慧, 大原利章, 田澤大, 白川靖博, 藤原俊義

日本消化器癌発生学会総会プログラム・抄録集 29th 2018

A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study)

Shunsuke Kagawa, Atsushi Muraoka, Takeshi Kambara, Hiroshi Nakayama, Ryosuke Hamano, Norimitsu Tanaka, Kazuhiro Noma, Kohji Tanakaya, Hiroyuki Kishimoto, Kunitoshi Shigeyasu, Shinji Kuroda, Satoru Kikuchi, Kazuya Kuwada, Masahiko Nishizaki, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

CANCER CHEMOTHERAPY AND PHARMACOLOGY 81 ( 2 ) 387 - 392 2018

Language：English Publisher：SPRINGER

Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study. The safety and efficacy of trastuzumab in combination with docetaxel and S-1 have not yet been evaluated.This study was a multicenter, phase II study. Patients with chemotherapy-na < ve HER2-positive advanced or metastatic GC were eligible. Trastuzumab was administered intravenously on day 1 of the first cycle at 8 and 6 mg/kg in subsequent cycles. Docetaxel was administered intravenously at 40 mg/m(2) on day 1 of each cycle. S-1 was administered at a dosage based on body surface area for 14 days in a 3-weekly cycle. The primary endpoint was progression-free survival (PFS).A total of 23 patients were enrolled. Median PFS was 6.7 months (95% CI 4.1-10.1). The response rate (RR) was 39.1%. Median overall survival (OS) and time to treatment failure (TTF) were 17.5 and 4.4 months, respectively. Major grade 3-4 adverse events were neutropenia (39.1%), leukopenia (30.4%), and febrile neutropenia (8.7%).Trastuzumab in combination with docetaxel and S-1 showed effective antitumor activity and manageable toxicities as first-line treatment for patients with HER2-positive GC.

DOI： 10.1007/s00280-017-3505-4

Web of Science

researchmap

Visualized Evaluation of Blood Flow to the Gastric Conduit and Complications in Esophageal Reconstruction. International journal

Kazuhiro Noma, Yasuhiro Shirakawa, Nobuhiko Kanaya, Tsuyoshi Okada, Naoaki Maeda, Takayuki Ninomiya, Shunsuke Tanabe, Kazufumi Sakurama, Toshiyoshi Fujiwara

Journal of the American College of Surgeons 226 ( 3 ) 241 - 251 2018

Language：English

BACKGROUND: Evaluation of the blood supply to gastric conduits is critically important to avoid complications after esophagectomy. We began visual evaluation of blood flow using indocyanine green (ICG) fluorescent imaging in July 2015, to reduce reconstructive complications. In this study, we aimed to statistically verify the efficacy of blood flow evaluation using our simplified ICG method. STUDY DESIGN: A total of 285 consecutive patients who underwent esophagectomy and gastric conduit reconstruction were reviewed and divided into 2 groups: before and after introduction of ICG evaluation. The entire cohort and 68 patient pairs after propensity score matching (PS-M) were evaluated for clinical outcomes and the effect of visualized evaluation on reducing the risk of complication. RESULTS: The leakage rate in the ICG group was significantly lower than in the non-ICG group for each severity grade, both in the entire cohort (285 subjects) and after PS-M; the rates of other major complications, including recurrent laryngeal nerve palsy and pneumonia, were not different. The duration of postoperative ICU stay was approximately 1 day shorter in the ICG group than in the non-ICG group in the entire cohort, and approximately 2 days shorter after PS-M. Visualized evaluation of blood flow with ICG methods significantly reduced the rate of anastomotic complications of all Clavien-Dindo (CD) grades. Odds ratios for ICG evaluation decreased with CD grade (0.3419 for CD ≥ 1; 0.241 for CD ≥ 2; and 0.2153 for CD ≥ 3). CONCLUSIONS: Objective evaluation of blood supply to the reconstructed conduit using ICG fluorescent imaging reduces the risk and degree of anastomotic complication.

DOI： 10.1016/j.jamcollsurg.2017.11.007

PubMed

researchmap

食道胃接合部癌切除後の観音開き法を用いた腹腔鏡下経裂孔食道残胃吻合

西崎正彦, 野間和広, 田邊俊介, 二宮卓之, 前田直見, 白川靖博, 藤原俊義

日本食道学会学術集会抄録集(CD-ROM) 72nd 2018

鞘と層の微細解剖に留意した左反回神経周囲リンパ節郭清手技定型化の工夫

白川靖博, 前田直見, 田辺俊介, 野間和広, 楳田祐三, 藤原俊義

日本胸部外科学会定期学術集会(Web) 71st 2018

食道癌外科診療における周術期チーム連携PERiO:Perioperative management center

白川靖博, 小川俊博, 前田直見, 二宮卓之, 田辺俊介, 野間和広, 楳田祐三, 西崎正彦, 香川俊輔, 藤原俊義

日本消化器外科学会雑誌(Web) 51 ( Supplement1 ) 2018

胸部食道癌手術における血流評価を元に行う安全な胃管・空腸再建法

野間和広, 白川靖博, 西脇紀之, 松田達雄, 前田直見, 田辺俊介, 藤原俊義

日本胸部外科学会定期学術集会(Web) 71st 2018

気道瘻を有する局所進行食道癌の開胸手術における合併症予防の工夫

田辺俊輔, 白川靖博, 西脇紀之, 松田達雄, 前田直見, 野間和広, 楳田祐三, 藤原俊義

日本臨床外科学会雑誌 79 2018

集学的治療を要する肺瘻合併胸部進行食道癌の一例

田辺俊介, 白川靖博, 前田直見, 野間和広, 藤原俊義

日本胸部外科学会定期学術集会(Web) 71st 2018

癌関連線維芽細胞は腫瘍浸潤リンパ球を制御することにより食道癌の予後に寄与する

加藤卓也, 加藤卓也, 野間和広, 賀島肇, 賀島肇, 桂佑貴, 桂佑貴, 前田直見, 二宮卓之, 田邊俊介, 白川靖博, 稲垣優, 藤原俊義

日本食道学会学術集会抄録集(CD-ROM) 72nd 2018

食道亜全摘手術患者における術前筋肉量が術後経過に与える影響

園井みか, 伊藤真理, 足羽孝子, 前田直見, 二宮卓之, 田邊俊介, 野間和広, 白川靖博, 藤原俊義, 森松博史

日本食道学会学術集会抄録集(CD-ROM) 72nd 2018

食道癌患者に対する腫瘍融解ウイルスの内視鏡的投与の実際-感染対策の取り組み-

矢野朋美, 采女典子, 森隆弘, 笠原由美子, 田辺俊介, 黒田新士, 野間和広, 田澤大, 香川俊輔, 白川靖博, 藤原俊義

日本消化器内視鏡技師学会プログラム・講演抄録 81st 2018

Suppression of Oncolytic Adenovirus-Mediated Hepatotoxicity by Liver-Specific Inhibition of NF-κB. International journal

Mitsuhiro Machitani, Fuminori Sakurai, Keisaku Wakabayashi, Kosuke Nakatani, Masashi Tachibana, Nobuyuki Kato, Toshiyoshi Fujiwara, Hiroyuki Mizuguchi

Molecular therapy oncolytics 7 76 - 85 2017.12

Language：English

Telomerase-specific replication-competent adenoviruses (Ads), i.e., TRADs, which possess an E1 gene expression cassette driven by the human telomerase reverse transcriptase promoter, are promising agents for cancer treatment. However, even though oncolytic Ads, including TRAD, are intratumorally administered, they are disseminated from the tumor to systemic circulation, causing concern about oncolytic Ad-mediated hepatotoxicity (due mainly to leaky expression of Ad genes in liver). We reported that inhibition of nuclear factor-κB (NF-κB) leads to the suppression of replication-incompetent Ad vector-mediated hepatotoxicity via reduction of the leaky expression of Ad genes in liver. Here, to develop a TRAD with an improved safety profile, we designed a TRAD that carries a liver-specific promoter-driven dominant-negative IκBα (DNIκBα) expression cassette (TRAD-DNIκBα). Compared with a conventional TRAD, TRAD-DNIκBα showed hepatocyte-specific inhibition of NF-κB signaling and significantly reduced Ad gene expression and replication in the normal human hepatocyte cell line. TRAD-induced hepatotoxicity was largely suppressed in mice following intravenous administration of TRAD-DNIκBα. However, the replication profiles and oncolytic activities of TRAD-DNIκBα were comparable with those of the conventional TRAD in human non-hepatic tumor cells. These results indicate that oncolytic Ads containing the liver-specific DNIκBα expression cassette have improved safety profiles without inhibiting oncolytic activities.

DOI： 10.1016/j.omto.2017.10.003

PubMed

researchmap

　 PREV - NEXT 　

< FUJIWARA Toshiyoshi >

MISC - FUJIWARA Toshiyoshi